Idorsia Ltd

IDIA

CH0363463438

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:30:41 2024-05-31 EDT			5-day change	1st Jan Change
2.594 ^CHF	+2.61%		+20.65%	+22.71%

05-21	Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05-21	Swiss Stocks Flash Red Amid Economic Data Focus in Europe	MT

Idorsia Ltd Appoints Simon Jose as Chief Commercial Officer, Effective December 1, 2018

October 22, 2018

Idorsia Ltd. announced that Simon Jose will join the company as Chief Commercial Officer on December 1, 2018. Mr. Jose will also be a member of the Idorsia Executive Committee.

Latest news about Idorsia Ltd

Idorsia Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	05-21	CI
Swiss Stocks Flash Red Amid Economic Data Focus in Europe	05-21	MT
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson...	05-21
Transcript : Idorsia Ltd, Q1 2024 Earnings Call, May 21, 2024	05-21
Idorsia to Implement Changes in Executive Committee Amid CEO Retirement	05-21	MT
Switzerland's Idorsia Posts Narrower FY23 Loss; Revenue Grows	05-21	MT
Idorsia Logs Lower Q1 Loss; Revenue Falls	05-21	MT
Idorsia Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds	05-07	MT
Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond	05-01	MT
Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	04-26	MT
Swiss Market Index Falls as ECB Signals June Rate Cut	04-11	MT
Idorsia to Revise July 2024 Convertible Bond Terms, Conditions	04-11	MT
Idorsia's Chief Medical Officer to Step Down at March-end; Successor Named	03-22	MT
Transcript : Idorsia Ltd - Special Call	03-20
US FDA OKs Idorsia's Hypertension Treatment in Combination with Other Antihypertensive Drugs	03-20	MT
Pharmaceutical Groups Idorsia, Viatris Finalize Collaboration to Develop Selatogrel, Cenerimod	03-18	MT
Idorsia, Viatris Partner to Develop, Commercialize Selatogrel, Cenerimod	02-28	MT
Sosei Group Changes Names of Company, Subsidiaries	02-16	MT
US Futures Slightly Down, European Stocks Edge Up	01-30	DJ
Transcript : Idorsia Ltd Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM	01-10
US Futures Mixed, European Stocks Mostly Down	01-10	DJ
Switzerland's Idorsia Seeks Additional Funding to Extend Cash Runway in FY24	01-10	MT
US Futures, European Stocks Climb	01-02	DJ
US Futures Climb, European Stocks Slip	12-18	DJ

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-06-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Idorsia Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

2.528 CHF

Average target price

1.692 CHF

Spread / Average Target

-33.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IDORSIA LTD	+22.71%	501M
VERTEX PHARMACEUTICALS INCORPORATED	+10.26%	114B
REGENERON PHARMACEUTICALS, INC.	+10.54%	105B
BIONTECH SE	-4.57%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-16.56%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.56%	13.75B
SAREPTA THERAPEUTICS, INC.	+32.24%	11.76B

Bio Therapeutic Drugs

Idorsia Ltd

Equities

IDIA

CH0363463438

Biotechnology & Medical Research

Idorsia Ltd Appoints Simon Jose as Chief Commercial Officer, Effective December 1, 2018

Latest news about Idorsia Ltd

Chart Idorsia Ltd

Company Profile

Income Statement Evolution

Ratings for Idorsia Ltd

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs